NZ285648A - Use of a metal complex as a metal peroxynitrite decomposition catalyst to treat diseases which are affected by accelerated decomposition of peroxynitrite - Google Patents

Use of a metal complex as a metal peroxynitrite decomposition catalyst to treat diseases which are affected by accelerated decomposition of peroxynitrite

Info

Publication number
NZ285648A
NZ285648A NZ285648A NZ28564895A NZ285648A NZ 285648 A NZ285648 A NZ 285648A NZ 285648 A NZ285648 A NZ 285648A NZ 28564895 A NZ28564895 A NZ 28564895A NZ 285648 A NZ285648 A NZ 285648A
Authority
NZ
New Zealand
Prior art keywords
peroxynitrite
metal
decomposition
affected
treat diseases
Prior art date
Application number
NZ285648A
Inventor
Michael Keith Stern
Daniela Salvemini
Original Assignee
Monsanto Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Monsanto Co filed Critical Monsanto Co
Publication of NZ285648A publication Critical patent/NZ285648A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
NZ285648A 1994-05-13 1995-05-09 Use of a metal complex as a metal peroxynitrite decomposition catalyst to treat diseases which are affected by accelerated decomposition of peroxynitrite NZ285648A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24249894A 1994-05-13 1994-05-13
PCT/US1995/005886 WO1995031197A1 (en) 1994-05-13 1995-05-09 Methods of use for peroxynitrite decomposition catalysts, pharmaceutical compositions therefor

Publications (1)

Publication Number Publication Date
NZ285648A true NZ285648A (en) 1999-08-30

Family

ID=22915009

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ285648A NZ285648A (en) 1994-05-13 1995-05-09 Use of a metal complex as a metal peroxynitrite decomposition catalyst to treat diseases which are affected by accelerated decomposition of peroxynitrite

Country Status (13)

Country Link
EP (1) EP0758892A1 (en)
JP (1) JPH10500671A (en)
CN (1) CN1222286C (en)
AU (1) AU709553B2 (en)
BR (1) BR9507643A (en)
CA (1) CA2189528A1 (en)
CZ (1) CZ323496A3 (en)
FI (1) FI964537A (en)
HU (1) HUT76327A (en)
NO (1) NO964793L (en)
NZ (1) NZ285648A (en)
PL (1) PL317192A1 (en)
WO (1) WO1995031197A1 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994339A (en) * 1993-10-15 1999-11-30 University Of Alabama At Birmingham Research Foundation Oxidant scavengers
US6127356A (en) * 1993-10-15 2000-10-03 Duke University Oxidant scavengers
AU3758695A (en) * 1994-09-20 1996-04-09 Duke University Oxidoreductase activity of manganic porphyrins
DE69813898T2 (en) 1997-11-03 2004-03-11 Duke University SUBSTITUTED PORPHYRINES
WO1999055388A1 (en) 1998-04-24 1999-11-04 Duke University Substituted porphyrins
US6632808B1 (en) 1998-08-11 2003-10-14 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors of amyloid formation
IL126953A0 (en) * 1998-11-08 1999-09-22 Yeda Res & Dev Pharmaceutical compositions comprising porphyrins and some novel porphyrin derivatives
EP1013272A1 (en) * 1998-12-23 2000-06-28 Biomedical Primate Research Centre (BPRC) Manipulation of the activity of a nitric oxide radical production pathway for the treatment of diseases associated with the presence of oxygen free radicals
CA2359116C (en) 1999-01-25 2009-03-17 National Jewish Medical And Research Center Substituted porphyrins
US6448239B1 (en) 1999-06-03 2002-09-10 Trustees Of Princeton University Peroxynitrite decomposition catalysts and methods of use thereof
FR2806911B1 (en) * 2000-03-28 2003-01-10 Univ Rene Descartes USE OF SOD MIMETICS IN THE TREATMENT OF HEPATOCELLULAR DEFICIENCIES
EP1392328B1 (en) * 2001-01-19 2009-08-12 National Jewish Medical and Research Center Medicament for protection in radiotherapy
AU2002312194B8 (en) 2001-06-01 2008-05-15 Aeolus Sciences, Inc. Oxidant scavengers for treatment of diabetes or use in transplantation or induction of immune tolerance
AU2003237500A1 (en) 2002-06-07 2003-12-22 Duke University Substituted porphyrins
DE10240343A1 (en) * 2002-08-27 2004-03-11 Schering Ag Peroxynitrite rearrangement catalysts
US6946466B2 (en) * 2003-04-10 2005-09-20 Schering Ag Aromatic sulfonamides as peroxynitrite-rearrangement catalysts
US7699964B2 (en) 2004-02-09 2010-04-20 Abbott Diabetes Care Inc. Membrane suitable for use in an analyte sensor, analyte sensor, and associated method
US8165651B2 (en) 2004-02-09 2012-04-24 Abbott Diabetes Care Inc. Analyte sensor, and associated system and method employing a catalytic agent
US7705040B2 (en) * 2005-10-07 2010-04-27 The University Of Hong Kong Reagents for highly specific detection of peroxynitrite
US7885698B2 (en) 2006-02-28 2011-02-08 Abbott Diabetes Care Inc. Method and system for providing continuous calibration of implantable analyte sensors
US8232267B2 (en) 2006-10-06 2012-07-31 The Trustees Of Princeton University Porphyrin catalysts and methods of use thereof
AU2008293376B2 (en) * 2007-08-28 2013-07-11 Technion Research & Development Foundation Ltd. Transition metal complexes of corroles for preventing cardiovascular diseases or disorders
EP2300003B1 (en) 2008-05-23 2014-03-05 National Jewish Health Compounds for use in treating injury associated with exposure to an alkylating species
WO2015102745A1 (en) 2013-12-31 2015-07-09 Abbott Diabetes Care Inc. Self-powered analyte sensor and devices using the same
RU2557655C1 (en) * 2014-06-10 2015-07-27 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Ивановский государственный химико-технологический университет" (ФГБОУ ВПО "ИГХТУ") Nickel complex of 5,10,15,20-tetrakis [3',5'-di(2"-methylbutyloxy)phenyl]-porphin, demonstrating property of stationary phase for gas chromatography
CN107573259A (en) * 2017-09-25 2018-01-12 沅江华龙催化科技有限公司 A kind of method of catalysis of metalloporphyrin aromatic olefin synthesis aromatic nitriles
EP4059496A1 (en) * 2021-03-18 2022-09-21 Institut Pasteur Mntbap and m(iii) n-substituted pyridylporphyrins (mnps) for use in reversing sepsis-induced microglial cells alteration(s), associated long-term cognitive impairment, and/or for treating sepsis or sepsis-associated encephalopathy (sae), and/or related short and/or long-term symptoms or complications thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1291710C (en) * 1985-04-30 1991-11-05 Jerry C. Bommer Tetrapyrrole therapeutic agents
DE3688253T2 (en) * 1986-01-02 1993-09-02 Univ Toledo PRODUCTION AND USE OF PREPARATIONS CONTAINING PURPLE, CHLORINE AND PURPINE AND CHLORINE.
US4866054A (en) * 1986-05-13 1989-09-12 Chai-Tech Corporation Antioxidant metallo-organic treatment of inflammation
EP0333831B1 (en) * 1987-09-08 1992-07-15 The Rockefeller University Use of metalloporphyrins to reverse the toxic effect of tumor therapy
ES2094795T3 (en) * 1990-11-02 1997-02-01 Ici Plc POLYUSTITUTED PHTHALOCIANINS.
WO1992008482A1 (en) * 1990-11-14 1992-05-29 Uab Research Foundation Compositions for reducing oxidative injury
FR2676738B1 (en) * 1991-05-22 1995-05-05 Ir2M NOVEL ORGANIC TRANSITION METAL WITH PORPHYRINIC STRUCTURE, THERAPEUTIC COMPOSITION CONTAINING SAME, IN PARTICULAR WITH HYPOGLYCEMIC ACTIVITY.
GB9111689D0 (en) * 1991-05-31 1991-07-24 Johnson Matthey Plc Gallium compounds
KR0145953B1 (en) * 1991-07-19 1998-08-17 제임스 클리프튼 보올딩 Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
CA2124204A1 (en) * 1991-11-25 1993-06-10 H. Dewayne Ashmead Composition and method for reducing free radical cellular oxidative stress in warm-blooded animals
US5296466A (en) * 1992-02-19 1994-03-22 Board Of Regents, The University Of Texas System Inhibition of nitric oxide-mediated hypotension and septic shock with iron-containing hemoprotein
US5403834A (en) * 1992-12-07 1995-04-04 Eukarion, Inc. Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
US6204259B1 (en) * 1993-01-14 2001-03-20 Monsanto Company Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
GB9309387D0 (en) * 1993-05-06 1993-06-16 Wellcome Found Nitric oxide scavengers
GB9317686D0 (en) * 1993-08-25 1993-10-13 Johnson Matthey Plc Pharmaceutical compositions

Also Published As

Publication number Publication date
HU9603140D0 (en) 1997-01-28
WO1995031197A1 (en) 1995-11-23
NO964793L (en) 1997-01-06
PL317192A1 (en) 1997-03-17
CA2189528A1 (en) 1995-11-23
AU2512095A (en) 1995-12-05
FI964537A0 (en) 1996-11-12
CN1152871A (en) 1997-06-25
EP0758892A1 (en) 1997-02-26
BR9507643A (en) 1997-09-23
FI964537A (en) 1997-01-10
CZ323496A3 (en) 1997-10-15
AU709553B2 (en) 1999-09-02
HUT76327A (en) 1997-08-28
CN1222286C (en) 2005-10-12
NO964793D0 (en) 1996-11-12
JPH10500671A (en) 1998-01-20

Similar Documents

Publication Publication Date Title
NZ285648A (en) Use of a metal complex as a metal peroxynitrite decomposition catalyst to treat diseases which are affected by accelerated decomposition of peroxynitrite
EP0740682A4 (en) Process for forming integral skin micorcellular structures
HU9700163D0 (en) Use of droloxifene for treatment of cardiovascular diseases
PL319785A1 (en) Pharmaceutic compositions for treating diseases caused by production of il-6
GB9422260D0 (en) Improvements relating to skin prickers
HU9500115D0 (en) Analogs of pth
HUP9700885D0 (en) New process for producing new compounds of pharmaceutical activity
EP0412456A3 (en) A process for the catalytic decomposition of chlorofluoro-alkanes
BR9611808A (en) Processes catalyzed to improved complex of metal molecules
AU4376396A (en) Use of andrographolide compounds to treat or prevent pathogenicity of diseases
GB2207866B (en) Use of metal chelates as mulluscicides
AU3234995A (en) Use of il-6 to treat toxic shock
US4931457B1 (en) Naphthylamino-and naphthyloxy-pyridineamin compounds useful as topical antiinflammatory agents for the treatment of skin disorders
PL336760A1 (en) Treatment of skin diseases
HU9400312D0 (en) Process for the preparation of a catalyst
EP0911034A4 (en) Medicinal compositions for treating cardiac diseases caused by cardiac hypertrophy
EP0859663A4 (en) Treatment of zeolite to improve its butene selectivity
HU906305D0 (en) Process for producing tetrazole-acetic derivatives of aldose-reductase inhibiting activity
AU518540B2 (en) Producing microbubbles to treat a suspension
IL116733A0 (en) The use of sertraline to treat cancer patients
HUP9801925A3 (en) Use of sodium-hydrogen-exchange-inhibitors for producing pharmaceutical compositions treating diseases caused by protozoons
AU524619B2 (en) Treating a patient by water sprays
HU9202483D0 (en) Multigen having self-splitting activity for expression of rna
ZA9189B (en) Treatment of protozoal diseases
IL118351A0 (en) Conversion of substituted 8-chloroquinolines to substituted 8-hydroxyquinolines

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)